GcMaf, a proteína

Antes de continuarmos sobre os problemas na abordagem dos tipos de terapias convencionais e falarmos sobre os tratamentos do câncer com sucesso por diversos médicos ao redor do mundo, vamos primeiramente comentar sobre o papel fundamental da vitamina D3 na prevenção não somente do câncer quanto a infecções, e como é imprescindível no tratamento do câncer. E nem estamos querendo com isso desencorajar o uso de terapias convencionais, o objectivo é levar informação.

Além dos inúmeros benefícios já publicados sobre a vitamina D3 Agora iremos demonstrar o porquê da importância da vitamina D3 no combate não somente ao câncer antes de sua iniciação/promoção, como também no aumento da imunidade contra as infecções. Comenta-se bastante sobre a importância da vitamina D3, mas poucos entendem o porquê. Como age quando o assunto é imunidade. A resistência a infecções depende da vitamina D e não da vitamina C, que é um antioxidante.

O organismo humano produz de cinco a onze mil células cancerosas por dia, porém, nosso sistema imune faz a supressão desses genes, isso porque o GcMAF está presente e o corpo consegue realizar o que precisa activando macrófagos e desencadeando os processos imunes, não somente contra células cancerígenas mas também contra vírus, fungos, bactérias... O GcMAF é um granulócito activador de macrófagos, descoberto pelo Dr. Nobuto Yamamoto.

O precursor do GcMAF é a GcProtein (Vitamin D3 Binding Globulin), a vitamina D3 é lipossolúvel, mas nosso sangue é hidrossolúvel, por conta disso, para que a Vitamina D3 possa ser transportada pelo sangue, torna-se necessário a presença de um transportador, que é a GcProtein, a qual, é a precursora do GcMAF. No caso de um indivíduo possuir deficiência ou insuficiência de vitamina D3, significa que além de não estar com o sistema imune forte, essa deficiência ou insuficiência predispõe ao câncer. Por isso a importância de manter os níveis de vitamina D3 no sangue em níveis entre 50 e 80 ng/ml. Em um paciente com câncer é imprescindível, que no mínimo, estes níveis estejam em 80 ng/ml. Existem provas científicas de que níveis bons de vitamina D3 no organismo são, de no mínimo, 40 ng/ml, diferentemente do que diz seus exames, cujos valores oscilam entre 30 e 35 ng/ml.

Não é nosso interesse demonstrar porque as referências dos exames são erradas, contudo, no tópico sobre vitamina D3 mostro o estudo que fala dos níveis ideais. Para resumir: níveis menores que 32 ng/ml (deficiência), níveis entre 32 e 50 ng/ml (insuficiência), níveis entre 50 e 80 ng/ml (óptimos). Os exames são muito errados, níveis normais tem como referência entre 32 e 100 ng/ml (ou seja, quem está com níveis acima de 50 e menor que 100 ng/ml está muito melhor do que quem está com 32 ng/ml).

Em outras palavras, quanto menor for os níveis séricos de vitamina D3 no organismo, mais susceptível a infecções, seja gripe, resfriados, cancros (antes de sua iniciação/promoção).

QUANTO SUPLEMENTAR DE VITAMINA D3?

Depende! Não existe uma dosagem que sirva para todas as pessoas, o importante é saber qual dosagem será suficiente para manter seus níveis entre 50 e 80 ng/ml. Convém, antes verificar os níveis séricos via exame e iniciar a suplementação. Como sugestão! pessoas com valores insuficientes podem começar com 10.000 ui/dia que é uma dose fisiológica. De preferência na forma sublingual ou em gotas, por serem mais facilmente e rapidamente assimiláveis. Em outras palavras, em um paciente com câncer deve-se fazer todos os meios para elevar os níveis de vitamina D3 no organismo. A partir do momento que os níveis séricos de vitamina D3 aumentarem, aumentaremos a GcProtein, que será convertida em GcMAF, e consequentemente o câncer é combatido. Isso vale, não apenas para cancro como também para todas as infecções

ENTENDENDO O GcMAF

A estrutura química da GcProtein é composta por 400 aminoácidos e três açúcares. Destes três açúcares, dois deles serão removidos pelos linfócitos B e linfócitos T e, como resultado, chega-se a uma estrutura que é o GcMAF, que irá realizar a activação dos macrófagos. Para entender isso vamos analisar a sequência de slides.

GcMAF não é medicamento (Macrophage Activating Factor), é um activador de macrófagos.

SLIDE 1

A estrutura da GcProtein é composto por 400 aminoácidos, terminando com a treonina (T) com mais três açúcares chamados de "N", "G", "S".

SLIDE 2

Os linfócitos B e T removem os açúcares B e T.

SLIDE 3

Após a remoção dos açúcares "G" e "S", fica apenas a estrutura acima. Que é o GcMAF.

SLIDE 4

A INTELIGÊNCIA DO CÂNCER

Agora iremos entender porque é importante fazer uso do GcMAF. A célula cancerígena também não quer morrer. Possui uma vontade própria, que garante a sua sobrevivência. Em face disso, produz uma enzima chamada Nagalase, que tem a função de inibir a formação do GcMAF, impedindo que o sistema imune possa reagir contra ela, conforme é mostrado na imagem seguinte. Dito isto, uma das formas de avaliar a severidade do câncer é medir os níveis de Nagalase no sangue, quanto maior os níveis mais agressivo será o câncer.

SLIDE 1

A célula cancerígena, produz a enzima Nagalase, que agora bloqueia os três açúcares, impedindo que os macrófagos sejam activados, causando uma diminuição da eficácia do sistema imune.

A IMUNOTERAPIA DO CÂNCER

Uma das formas de combater o câncer seria então fazer uso do GcMAF, esse tratamento existe, pode ser comprado no exterior por exemplo. No site GcMaf.se.

Injeções de GcMAF podem ser compradas na Alemanha.

Fonte: GcMAF.se https://gcmaf.se/

"No seu papel de regulador do sistema imunológico, a pesquisa mostra que GcMAF pode reverter outras doenças que atacam o sistema imunitário, como o autismo, CFS, XMRV, doença de Lyme, sida, HIV, fibromialgia, osteoporose, doença de Hodgkin, lúpus, esclerose múltipla, Parkinson, várias infecções bacterianas e virais e vários tipos de disfunção do sistema imunológico.

E ainda existe um iogurte que fornece GcMAF, um probiótico da Bravo, que é tido como o melhor iogurte do mundo, por sua capacidade de fornecer o GcMAF.

Saiba mais

https://www.bravo-probiotics.com/store/p13/BRAVO_PROBIOTICS_YOGURT_KIT_-_MAKES_GCMAF_IN_YOUR_GUT_-_3_MONTH_SUPPLY_-_NOW_PERMANENTLY_REDUCED_TO_US$495_SAVE_$100_.html

https://www.marsvenus.com/p/gcmaf-bravo-probiotic-yogurt

Existem inúmeros trabalhos científicos recentes desde 2013, demonstrando o poder do uso do GcMAF. Conforme mostraremos abaixo..

GC Protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients

www.ncbi.nlm.nih.gov/pmc/articles/PMC3812199/

Níveis de Nagalase antes e depois da aplicação da terapia com GcMAF

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812199/table/T1/

Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2510818/

AntiCancer Research

Gc Protein (Vitamin D-binding Protein): Gc Genotyping and GcMAF Precursor Activity

https://ar.iiarjournals.org/content/25/6A/3689.short

Journal of the National Cancer Institute

Effects of Vitamin D3-Binding Protein-Derived Macrophage Activating Factor (GcMAF) on Angiogenesis

https://jnci.oxfordjournals.org/content/94/17/1311.short

Translational Oncology

Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF 1

https://www.sciencedirect.com/science/article/pii/S1936523308800083

Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation

https://www.sciencedirect.com/science/article/pii/S1095643301005220

Mais trabalhos com o uso do GcMAF

https://scholar.google.com.br/scholar?q=GcMAF&btnG=&hl=pt-BR&as_sdt=0%2C5References

1. Yamamoto N, Naraparaju VR, Moore M, Brent LH. Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. Clin Immunol Immunopathol. 1997;82:290-8. doi: 10.1006/clin.1996.4320. [PubMed] [Cross Ref]

2. Mohamad SB, Nagasawa H, Uto Y, Hori H. Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation. Comp Biochem Physiol A Mol Integr Physiol. 2002;132:1-8. doi: 10.1016/S1095-6433(01)00522-0. [PubMed] [Cross Ref]

3. Greco M, Mitri MD, Chiriacò F, Leo G, Brienza E, Maffia M. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Lett. 2009;283:222-9. doi: 10.1016/j.canlet.2009.04.001. [PubMed] [Cross Ref]

4. Reddi AL, Sankaranarayanan K, Arulraj HS, Devaraj N, Devaraj H. Serum alpha-N-acetylgalactosaminidase is associated with diagnosis/prognosis of patients with squamous cell carcinoma of the uterine cervix. Cancer Lett. 2000;158:61-4. doi: 10.1016/S0304-3835(00)00502-4. [PubMed] [Cross Ref]

5. Yamamoto N, Suyama H, Yamamoto N, Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF) Int J Cancer. 2008;122:461-7. doi: 10.1002/ijc.23107. [PubMed] [Cross Ref]

6. Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol Immunother. 2008;57:1007-16. doi: 10.1007/s00262-007-0431-z. [PubMed] [Cross Ref]

7. Yamamoto N, Suyama H, Yamamoto N. Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. Transl Oncol. 2008;1:65-72. [PMC free article] [PubMed]

8. Nonaka K, Onizuka S, Ishibashi H, Uto Y, Hori H, Nakayama T, et al. Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice. J Surg Res. 2012;172:116-22. doi: 10.1016/j.jss.2010.07.057. [PubMed] [Cross Ref]

9. Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, et al. Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One. 2010;5:e13428. doi: 10.1371/journal.pone.0013428. [PMC free article] [PubMed] [Cross Ref]

10. Pacini S, Punzi T, Morucci G, Gulisano M, Ruggiero M. Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells. Anticancer Res. 2012;32:45-52. [PubMed]

11. Kalkunte S, Brard L, Granai CO, Swamy N. Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf. Angiogenesis. 2005;8:349-60. doi: 10.1007/s10456-005-9024-7. [PubMed] [Cross Ref]

12. Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M. Gc protein-derived macrophage-activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay. Cancer Immunol Immunother. 2011;60:479-85. doi: 10.1007/s00262-010-0953-7. [PubMed] [Cross Ref]

13. Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M, Amato M, et al. Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling. J Nephrol. 2012;25:577-81. doi: 10.5301/jn.5000035. [PubMed] [Cross Ref]

14. Yamamoto N, Naraparaju VR, Urade M. Prognostic utility of serum alpha-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res. 1997;57:295-9. [PubMed]

15. Yamamoto N, Lindsay DD, Naraparaju VR, Ireland RA, Popoff SN. A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats. J Immunol. 1994;152:5100-7. [PubMed]

16. Nunn R. Mere anecdote: evidence and stories in medicine. J Eval Clin Pract. 2011;17:920-6. doi: 10.1111/j.1365-2753.2011.01727.x. [PubMed] [Cross Ref]

17. Yamamoto N, Ushijima N, Koga Y. Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF) J Med Virol. 2009;81:16-26. doi: 10.1002/jmv.21376. [PubMed] [Cross Ref]

18. Bradstreet JJ, Vogelaar E, Thyer L. Initial observations of elevated alpha-N-acetylgalactosaminidase activity associated with autism and observed reductions from GC protein-macrophage activating factor injections. Autism Insights. 2012;4:31-8. doi: 10.4137/AUI.S10485. [Cross Ref]

19. Fabris A, Biagioni P, Punzi T, Morucci G, Gulisano M, Pacini S, et al. Role of angiotensin-converting enzyme and vitamin D receptor gene polymorphisms in cancer anorexia-cachexia syndrome. Am J Immunol. 2012;8:65-70.

20. Rehder DS, Nelson RW, Borges CR. Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci. 2009;18:2036-42. doi: 10.1002/pro.214. [PMC free article] [PubMed] [Cross Ref]

21. Inui T, Kuchiike D, Kubo K, Mette M, Uto Y, Hori H, et al. Clinical Experience of Integrative Cancer Immunotherapy with GcMAF. Anticancer Res. 2013;33:2917-9. [PubMed]

22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54. doi: 10.1016/0003-2697(76)90527-3. [PubMed] [Cross Ref]

1: Toyohara Y, Hashitani S, Kishimoto H, Noguchi K, Yamamoto N, Urade M. Inhibitory effect of vitamin D-binding protein-derived macrophage activating factor on DMBA-induced hamster cheek pouch carcinogenesis and its derived carcinoma cell line. Oncol Lett. 2011 Jul;2(4):685-691. Epub 2011 May 13. PubMed PMID: 22848250; PubMed Central PMCID: PMC3406437.

2: Bellone M, Rigamonti N. Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer. Cancer Immunol Immunother. 2012 Dec;61(12):2377-8. doi: 10.1007/s00262-012-1310-9. Epub 2012 Jun 28. PubMed PMID: 22740161.

3: Uto Y, Yamamoto S, Mukai H, Ishiyama N, Takeuchi R, Nakagawa Y, Hirota K, Terada H, Onizuka S, Hori H. ?-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF. Anticancer Res. 2012 Jun;32(6):2359-64. PubMed PMID: 22641675.

4: Pacini S, Punzi T, Morucci G, Gulisano M, Ruggiero M. Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells. Anticancer Res. 2012 Jan;32(1):45-52. PubMed PMID: 22213287.

5: Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M, Amato M, Aterini S. Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling. J Nephrol. 2012 Jul-Aug;25(4):577-81. doi: 10.5301/jn.5000035. PubMed PMID: 21956771.

6: Uto Y, Yamamoto S, Takeuchi R, Nakagawa Y, Hirota K, Terada H, Onizuka S, Nakata E, Hori H. Effect of the Gc-derived macrophage-activating factor precursor (preGcMAF) on phagocytic activation of mouse peritoneal macrophages. Anticancer

Res. 2011 Jul;31(7):2489-92. PubMed PMID: 21873164.

7: Debruyne E, Speeckaert M, Weygaerde YV, Delanghe J. Phenotype of Gc-globulin influences the macrophage activating factor (MAF) levels in serum. Clin Chem Lab Med. 2011 Nov;49(11):1855-60. doi: 10.1515/CCLM.2011.676. Epub 2011 Aug 23. PubMed PMID: 21859424.

8: Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M. Gc protein-derived macrophage-activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic

membrane assay. Cancer Immunol Immunother. 2011 Apr;60(4):479-85. doi: 10.1007/s00262-010-0953-7. Epub 2010 Dec 14. PubMed PMID: 21170647.

9: Faserl K, Golderer G, Kremser L, Lindner H, Sarg B, Wildt L, Seeber B. Polymorphism in vitamin D-binding protein as a genetic risk factor in the pathogenesis of endometriosis. J Clin Endocrinol Metab. 2011 Jan;96(1):E233-41. doi: 10.1210/jc.2010-1532. Epub 2010 Oct 27. PubMed PMID: 20980430.

10: Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, Huang B, Pirie-Shepherd S, Fannon M. Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One. 2010 Oct 18;5(10):e13428. doi: 10.1371/journal.pone.0013428. PubMed PMID: 20976141; PubMed Central PMCID: PMC2956649.

11: Nonaka K, Onizuka S, Ishibashi H, Uto Y, Hori H, Nakayama T, Matsuura N, Kanematsu T, Fujioka H. Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice. J Surg Res. 2012 Jan;172(1):116-22. doi: 10.1016/j.jss.2010.07.057. Epub 2010 Sep 17. PubMed PMID: 20855083.

12: Ravnsborg T, Olsen DT, Thysen AH, Christiansen M, Houen G, Højrup P. The glycosylation and characterization of the candidate Gc macrophage activating factor. Biochim Biophys Acta. 2010 Apr;1804(4):909-17. doi: 10.1016/j.bbapap.2009.12.022. Epub 2010 Jan 13. PubMed PMID: 20079467.

13: Rehder DS, Nelson RW, Borges CR. Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci. 2009 Oct;18(10):2036-42. doi: 10.1002/pro.214. PubMed PMID: 19642159; PubMed Central PMCID: PMC2786967.

14: Fang Y, van Meurs JB, Arp P, van Leeuwen JP, Hofman A, Pols HA, Uitterlinden AG. Vitamin D binding protein genotype and osteoporosis. Calcif Tissue Int. 2009 Aug;85(2):85-93. doi: 10.1007/s00223-009-9251-9. Epub 2009 Jun 2. PubMed PMID: 19488670; PubMed Central PMCID: PMC2729412.

15: Yamamoto N, Ushijima N, Koga Y. Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). J Med Virol. 2009 Jan;81(1):16-26. doi: 10.1002/jmv.21376. PubMed PMID: 19031451.

16: Yamamoto N, Suyama H, Yamamoto N. Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. Transl Oncol. 2008 Jul;1(2):65-72. PubMed PMID: 18633461; PubMed Central PMCID: PMC2510818.

17: Spiriti J, Bogani F, van der Vaart A, Ghirlanda G. Modulation of protein stability by O-glycosylation in a designed Gc-MAF analog. Biophys Chem. 2008 May;134(3):157-67. doi: 10.1016/j.bpc.2008.02.005. Epub 2008 Feb 21. PubMed PMID: 18329161.

18: Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol Immunother. 2008

Jul;57(7):1007-16. PubMed PMID: 18058096.

19: Yamamoto N, Suyama H, Yamamoto N, Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer. 2008 Jan 15;122(2):461-7. PubMed PMID:17935130.

20: Meier U, Gressner O, Lammert F, Gressner AM. Gc-globulin: roles in response to injury. Clin Chem. 2006 Jul;52(7):1247-53. Epub 2006 May 18. Review. PubMed PMID: 16709624.

21: Kalkunte S, Brard L, Granai CO, Swamy N. Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf. Angiogenesis. 2005;8(4):349-60. Epub 2006 Jan 7. PubMed PMID: 16400520.

22: Yamamoto N, Urade M. Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the hemagglutinin of influenza virus. Microbes Infect. 2005 Apr;7(4):674-81. Epub 2005 Mar 22. PubMed PMID: 15848273.

23: Nagasawa H, Sasaki H, Uto Y, Kubo S, Hori H. Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein. Anticancer Res. 2004 Sep-Oct;24(5C):3361-6. PubMed PMID: 15515432.

24: Onizuka S, Kawakami S, Taniguchi K, Fujioka H, Miyashita K. Pancreatic carcinogenesis: apoptosis and angiogenesis. Pancreas. 2004 Apr;28(3):317-9. PubMed PMID: 15084979.

25: Matsuura T, Uematsu T, Yamaoka M, Furusawa K. Effect of salivary gland adenocarcinoma cell-derived alpha-N-acetylgalactosaminidase on the bioactivity of macrophage activating factor. Int J Oncol. 2004 Mar;24(3):521-8. PubMed PMID: 14767536.

26: Schneider GB, Grecco KJ, Safadi FF, Popoff SN. The anabolic effects of vitamin D-binding protein-macrophage activating factor (DBP-MAF) and a novel small peptide on bone. Crit Rev Eukaryot Gene Expr. 2003;13(2-4):277-84. PubMedPMID: 14696974.

27: Mohamad SB, Nagasawa H, Sasaki H, Uto Y, Nakagawa Y, Kawashima K, Hori H. Gc protein-derived macrophage activating factor (GcMAF): isoelectric focusing pattern and tumoricidal activity. Anticancer Res. 2003 Nov-Dec;23(6a):4451-7. PubMed PMID: 14666733.

28: Gumireddy K, Reddy CD, Swamy N. Mitogen-activated protein kinase pathway mediates DBP-maf-induced apoptosis in RAW 264.7 macrophages. J Cell Biochem. 2003 Sep 1;90(1):87-96. PubMed PMID: 12938159.

29: Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, Zetter B, Folkman J, Ray R, Swamy N, Pirie-Shepherd S. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice.

Neoplasia. 2003 Jan-Feb;5(1):32-40. PubMed PMID: 12659668; PubMed Central PMCID: PMC1502120.

30: Mohamad SB, Nagasawa H, Uto Y, Hori H. Preparation of Gc protein-derived macrophage activating factor (GcMAF) and its structural characterization and biological activities. Anticancer Res. 2002 Nov-Dec;22(6C):4297-300. PubMed PMID:12553073.

31: Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N. Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. J Natl Cancer Inst. 2002 Sep 4;94(17):1311-9. PubMed PMID: 12208896.

32: Swamy N, Ghosh S, Schneider GB, Ray R. Baculovirus-expressed vitamin D-binding protein-macrophage activating factor (DBP-maf) activates osteoclasts and binding of 25-hydroxyvitamin D(3) does not influence this activity. J Cell Biochem. 2001;81(3):535-46. PubMed PMID: 11255236.

33: Kanan RM, Cook DB, Datta HK. Lectin immunoassay for macrophage-activating factor (Gc-MAF) produced by deglycosylation of Gc-globulin: evidence for noninducible generation of Gc-MAF. Clin Chem. 2000 Mar;46(3):412-4. PubMed PMID: 10702530.

34: Odgren PR, Popoff SN, Safadi FF, MacKay CA, Mason-Savas A, Seifert MF, Marks SC Jr. The toothless osteopetrotic rat has a normal vitamin D-binding protein-macrophage activating factor (DBP-MAF) cascade and chondrodysplasia resistant to treatments with colony stimulating factor-1 (CSF-1) and/or DBP-MAF. Bone. 1999 Aug;25(2):175-81. PubMed PMID: 10456382.

35: Koga Y, Naraparaju VR, Yamamoto N. Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice. Proc Soc Exp Biol Med. 1999 Jan;220(1):20-6. PubMed PMID: 9893164.

36: Adebanjo OA, Moonga BS, Haddad JG, Huang CL, Zaidi M. A possible new role for vitamin D-binding protein in osteoclast control: inhibition of extracellular Ca2+ sensing at low physiological concentrations. Biochem Biophys Res Commun. 1998 Aug 28;249(3):668-71. PubMed PMID: 9731194.

37: Yamamoto N, Naraparaju VR. Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization. Immunol Cell Biol. 1998 Jun;76(3):237-44. PubMed PMID: 9682967.

38: Yamamoto N, Naraparaju VR. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res. 1997 Jun 1;57(11):2187-92. PubMed PMID: 9187119.

39: Yamamoto N, Naraparaju VR, Moore M, Brent LH. Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. Clin Immunol Immunopathol.

1997 Mar;82(3):290-8. PubMed PMID: 9073553.

40: Yamamoto N, Naraparaju VR, Urade M. Prognostic utility of serum alpha-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res. 1997 Jan

15;57(2):295-9. PubMed PMID: 9000571.

41: Korbelik M, Naraparaju VR, Yamamoto N. Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer. 1997;75(2):202-7. PubMed PMID: 9010027; PubMed Central PMCID: PMC2063270.

42: Benis KA, Schneider GB. The effects of vitamin D binding protein-macrophage activating factor and colony-stimulating factor-1 on hematopoietic cells in normal and osteopetrotic rats. Blood. 1996 Oct 15;88(8):2898-905. PubMed PMID:8874186.

43: Yamamoto N. Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production. Mol Immunol. 1996 Oct;33(15):1157-64. PubMed PMID: 9070663.

44: Yamamoto N, Naraparaju VR. Role of vitamin D3-binding protein in activation of mouse macrophages. J Immunol. 1996 Aug 15;157(4):1744-9. PubMed PMID: 8759764.

45: Yamamoto N, Naraparaju VR, Orchard PJ. Defective lymphocyte glycosidases in the macrophage activation cascade of juvenile osteopetrosis. Blood. 1996 Aug 15;88(4):1473-8. PubMed PMID: 8695868.

46: Yamamoto N, Naraparaju VR. A defect in inducible beta-galactosidase of B lymphocytes in the osteopetrotic (mi/mi) mouse. Immunology. 1996 Aug;88(4):604-10. PubMed PMID: 8881764; PubMed Central PMCID: PMC1456628.

47: Yamamoto N, Naraparaju VR, Asbell SO. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res. 1996 Jun 15;56(12):2827-31. PubMed PMID: 8665521.

48: Yamamoto N, Naraparaju VR. Vitamin D3-binding protein as a precursor for macrophage activating factor in the inflammation-primed macrophage activation cascade in rats. Cell Immunol. 1996 Jun 15;170(2):161-7. PubMed PMID: 8660814.

49: Yamamoto N, Naraparaju VR. A defect in beta-galactosidase of B lymphocytes in the osteopetrotic (op/op) mouse. Immunol Lett. 1996 Apr;50(1-2):35-40. PubMed PMID: 8793557.

50: Yamamoto N, Naraparaju VR, Srinivasula SM. Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients. AIDS Res Hum Retroviruses. 1995 Nov;11(11):1373-8. PubMed PMID: 8573395.

51: Schneider GB, Benis KA, Flay NW, Ireland RA, Popoff SN. Effects of vitamin D binding protein-macrophage activating factor (DBP-MAF) infusion on bone resorption in two osteopetrotic mutations. Bone. 1995 Jun;16(6):657-62. PubMedPMID: 7669443.

52: Naraparaju VR, Yamamoto N. Roles of beta-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation-primed activation of macrophages. Immunol Lett. 1994 Dec;43(3):143-8. PubMed PMID: 7721326.

53: Yamamoto N, Willett NP, Lindsay DD. Participation of serum proteins in the inflammation-primed activation of macrophages. Inflammation. 1994 Jun;18(3):311-22. PubMed PMID: 8088927.

54: Yamamoto N, Lindsay DD, Naraparaju VR, Ireland RA, Popoff SN. A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats. J Immunol. 1994 May 15;152(10):5100-7. PubMed PMID: 8176226.

55: Yamamoto N, Kumashiro R. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. J Immunol. 1993 Sep 1;151(5):2794-802. PubMed PMID: 8360493.

56: Homma S, Yamamoto M, Yamamoto N. Vitamin D-binding protein (group-specific component) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine. Immunol Cell Biol. 1993 Aug;71 ( Pt 4):249-57. PubMed PMID: 8225394.

57: Yamamoto N, Homma S, Haddad JG, Kowalski MA. Vitamin D3 binding protein required for in vitro activation of macrophages after alkylglycerol treatment of mouse peritoneal cells. Immunology. 1991 Nov;74(3):420-4. PubMed PMID: 1769691; PubMed Central PMCID: PMC1384634.

58: Yamamoto N, Homma S. Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8539-43. PubMed PMID: 1924312; PubMed Central PMCID: PMC52544.

59: Yamamoto N, Homma S, Millman I. Identification of the serum factor required for in vitro activation of macrophages. Role of vitamin D3-binding protein (group specific component, Gc) in lysophospholipid activation of mouse peritonealmacrophages. J Immunol. 1991 Jul 1;147(1):273-80. PubMed PMID: 2051023.

60. https://www.saisei-mirai.or.jp/gan/pdf/20140629-indications-gcmaf-immunotherapy-cancers-chronic-viral-bacterial-infections-toshio-inui.pdf

61. https://www.saisei-mirai.or.jp/gan/macrophage_eng.html

62. https://immunocentre.eu/research-papers/

63. https://efranat.com/

64. https://www.lifeextension.com/About/Lef-Funding-Scientific-Research

65. https://claumarcelino.blogspot.com.br/2012/02/vit-d-e-autismo-gcmaf-e-nagalase.html